Du et al. indicated that hsa-miR-184 can be involved in the Wnt/beta-catenin signaling pathway and that the inhibition of hsa-miR-184 might reduce the tumor volume of osteosarcoma [32]. This evidence concerns the gene CTNNB1 and neoplasm.